Management volunteers specific, checkable numbers about the near future — quantified forward commitments it could visibl
The model's full reasoning — Q4 2021 call → NOWe need to determine if management volunteers specific, checkable numbers or dates about what the company's own business will do in the near term, presented as commitments describing a step-up from current level, grounded in things management says it can already see. The transcript includes financial guidance for 2022: net product sales from both HETLIOZ and Fanapt of between $240 million and $280 million; HETLIOZ net product sales of between $150 million and $180 million; Fanapt net product sales of between $90 million and $100 million; year-end 2022 cash of greater than $440 million. This is forward guidance, but it's routine financial guidance. The question says: "Answer NO if the only forward numbers given are routine next-quarter or full-year financial guidance ranges (revenue, EPS, margin, capex) delivered in the ordinary way without a described step-up in the business's activity level." Here, the guidance is for full-year 2022. Is there a described step-up? The guidance for HETLIOZ is $150-180 million, while 2021 HETLIOZ net product sales were $173.5 million. So the guidance range includes a decline from 2021. Fanapt guidance is $90-100 million, while 2021 Fanapt net product sales were $95.1 million, so roughly flat. Total revenues 2021 were $268.7 million, guidance $240-280 million, so possibly flat or down. So this is not a step-up; it's continuation or possibly decline. Also, the guidance is routine. Are there other specific numbers? They mention "more than 50 patients with SMS are currently on treatment" but that's current, not forward. They mention "Phase III study of bipolar disorder which is now over 50% enrolled and expected to complete enrollment by the end of 2022" - that's a specific date and a step-up? But it's about a clinical trial, not business activity like sales. The question asks about "what the company's own business will do in the near term" - could include clinical milestones? But the context is about business performance, like production, sales, etc. The guidance is the main forward numbers. Also, they mention "We expect first quarter 2022 HETLIOZ revenue to be impacted by the annual Medicare manufacturer contribution and the annual payer disruption" - that's a qualitative statement, not a specific number. The question specifically says: "Answer YES when management's own words convey...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| DXLG | Destination XL Group, Inc. | Q2 2023 | 2023-08-24 | D |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| CHUY | Chuy's Holdings, Inc. | Q3 2022 | 2022-11-05 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SQM | Sociedad Química y Minera de Chile S.A. | Q1 2022 | 2022-05-19 | C+ |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
TWO · Q2 2022 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term that show a step-up, grounded in things they can already see....YES The transcript shows management volunteering a concrete, checkable commitment on the RoundPoint acquisition: they expect incremental annual pre-tax earnings of approximately $20 million once the portfolio is fully transferred (with Mary Riskey later confirming $0.45 per share after-tax accretion). They also state they will begin transitioning loans to Round Point as a subservicer later this year and expect the acquisition to close in 2023. These are presented as owned expectations tied to the in-house servicing model they are already executing, describing a clear step-up in earnings and operational activity above the current subservicing level.
CUBI · Q3 2018 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term, presenting them as commitments for a step-up from current le...YES Management volunteers concrete, checkable commitments for the near term (next 12–18 months) that describe a clear step-up from current levels and are grounded in things already in motion or in hand. Examples include: - NIM target of 2.75% within 12–18 months, explicitly tied to 3–4 rate hikes and the $495 million securities sale plus $500 million borrowings repayment already executed. - $600 million core-franchise deposit growth + $500–600 million CB digital + $500 million BankMobile white-label deposits next year, building on the $1.
ADPT · Q4 2022 → YESThe question is: Does management volunteer specific, checkable numbers or dates about what the company's own business will do in the near term — quantified forward commitments concrete enough that inv...YES Management volunteers concrete, checkable commitments for 2023 that describe a clear step-up: full-year revenue of $205–215 million (versus $185.3 million in 2022), clonoSEQ test volumes growing more than 50% from the current base, MRD pharma milestones in the mid to high-single-digit millions, community business reaching 20% of total revenue (from 15% currently), and 2023 OpEx (including cost of revenue) slightly below the 2022 level of $385.5 million, with average quarterly cash burn of $40 million.